psilocybin (COMP360) / Compass Pathways  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
psilocybin (COMP360) / Compass Pathways
NCT06247839: The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

Not yet recruiting
3
20
NA
Psilocybin
Massachusetts General Hospital, COMPASS Pathways
Major Depressive Disorder
06/26
06/26
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Recruiting
3
255
US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
10/24
07/25
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25

Download Options